CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that we
CAMBRIDGE, Mass., November 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth.
Truist cut Alnylam to hold on Amvuttra sales uncertainty, lowering forecasts and price target. Read more here.
2026-10-30. The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals' (ALNY) fundamentals remain strong despite the company's expectation of 2026
Alnylam stock plunged after Q3 earnings beat as US Amvuttra demand slowed and costs rose. Read more here.
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Alnylam (ALNY) delivered earnings and revenue surprises of +642.47% and +0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
This is the newest page. Registered accounts read further back.